No abstract

No abstract

Background. The thyrotropin-secreting adenomas are very rare and even more rare when they simultaneously coexist with thyroid carcinoma. So far, only sixteen cases have been reported in the literature. Here, we present a unique case of successful management of a concurrent case of thyrotropin-prolactinoma with papillary thyroid carcinoma. Case Presentation. A 50-year-old Moroccan woman underwent a total thyroidectomy and complementary totalization by iratherapy for papillary thyroid carcinoma, who presented persistence of an inappropriate secretion of the thyroid-stimulating hormone (TSH > 4 mUI/L) despite of levothyroxine suppressive therapy (300 μg/d). After eliminating noncompliance, interfering medicines, and thyroid malabsorption, a pituitary adenoma (12 mm) was documented at magnetic resonance imaging. The patient has had transsphenoidal pituitary adenomectomy with histology confirming a thyrotropin-prolactin-secreting adenoma. After surgery and lanreotide treatment failures, we noted a complete response (TSH < 0.5) with cabergoline treatment (3 mg/week). Conclusion. The unusual association of thyroid adenocarcinoma and TSHoma enriches the hypothesis of a potential link between thyrotropic hypersecretion and thyroid carcinogenesis. Our case also illustrates the difficulty of monitoring thyroid carcinoma in nonremission of a TSHoma.

We related the case of medullary thyroid carcinoma, revealed by multiple inaugural pharyngolaryngeal metastases, requiring the use of a rescue tracheotomy. Their histopathology confirmed by laryngeal biopsy performed during a panendoscopy of the upper aerodigestive tract. Following the exclusion of remote metastases by positron emission tomography scan, a mutation of the RET protooncogene was investigated, allowing the family nature of the carcinoma to be excluded. The patient received an external radiotherapy with a palliative aim in front of the inextricable character of the tumor. Therapeutic modalities of this rare form of pharyngolaryngeal localization of medullary thyroid carcinoma are discussed.